TWi Biotechnology’s AC-201 secures FDA orphan drug status for epidermolysis bullosa
AC-201 has shown the ability to inhibit the production and activity of caspase-1 and the cytokine Interleukin-1Beta (IL-1Beta) and to down-regulate IL-1Beta receptors. Inhibition of IL-1Beta signaling has